Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.04.005
Héctor Carlos García-Díaz , María Larrosa-Garcia , Javier Gómez-Alonso , Mara Cruellas , Enriqueta Felip , Teresa Macarulla , Anna Farriols , Maria J. Carreras
Objective
To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.
Methods
A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.
Results
A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of BRCA2 (PALB2) intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (ATM) non-small cell lung adenocarcinoma, somatic breast cancer gene (sBRCA2) colorectal cancer, germinal breast cancer gene 2 (gBRCA2) breast neuroendocrine tumor, gBRCA2 ampullary cancer and gBRCA2 pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.
Conclusions
There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes, like PALB2 and ATM and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.
{"title":"[Artículo traducido] Uso fuera de indicación de olaparib en localizaciones tumorales poco frecuentes en pacientes con genes alterados de la recombinación homóloga","authors":"Héctor Carlos García-Díaz , María Larrosa-Garcia , Javier Gómez-Alonso , Mara Cruellas , Enriqueta Felip , Teresa Macarulla , Anna Farriols , Maria J. Carreras","doi":"10.1016/j.farma.2025.04.005","DOIUrl":"10.1016/j.farma.2025.04.005","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.</div></div><div><h3>Methods</h3><div>A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.</div></div><div><h3>Results</h3><div>A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of <em>BRCA2</em> (<em>PALB2)</em> intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (<em>ATM)</em> non-small cell lung adenocarcinoma, somatic breast cancer gene (<em>sBRCA2)</em> colorectal cancer, germinal breast cancer gene 2 (<em>gBRCA2)</em> breast neuroendocrine tumor, <em>gBRCA2</em> ampullary cancer and <em>gBRCA2</em> pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.</div></div><div><h3>Conclusions</h3><div>There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes<em>,</em> like <em>PALB2</em> and <em>ATM</em> and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T286-T290"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.08.002
Montserrat Pérez-Encinas , Eva Negro-Vega , Cecilia M. Fernández-Llamazares
Purpose
To present results of the 2022 SEFH-Survey on Spanish Hospital Pharmacy Departments covering care, staffing, resources, technology, education, and research.
Method
A cross-sectional descriptive study via a voluntary online survey sent to 353 hospitals in Spain. Data were collected from July–December 2022. Long-stay hospitals and correctional facilities were excluded.
Results
Response rate was 54.1%. Public hospitals represented 62.6%. Only 10.1% of departments operated 24/7, rising to 39.3% in larger hospitals. Half lacked continuous care service. Outpatients' services operated in mornings and afternoons in 54.8% of them (78.6% in larger centers). Telepharmacy for outpatients reached 57.7% of hospitals. ISO 9000 standards were followed by 70.7% and 14.4% adopted the Joint Commission model.
Each department had on average 7.0 specialist pharmacists (8.8 in public hospitals; 3.9 in private), increasing to 13.4 in larger hospitals. Of these, 3.8 pharmacists worked at least half-time in clinical units. Pharmacy technicians were the most common non-pharmacist professionals (mean: 6.9). Including residents, 9.936 professionals worked in Hospital Pharmacy Departments nationwide.
Automated dispensing carousels averaged 0.4 (horizontal) and 1.1 (vertical) per department. Automated dispensing systems covered 19.8% of beds. Robotic outpatient dispensing existed in 20.0% of hospitals. Technology for sterile workflow was used in 45.3%, 10.0% had robotics for cytostatic compounding and 61.7% smart infusion pumps.
Pharmaceutical care was provided in emergency services in 39.8% of hospitals, rising to 67.4 in larger ones. In home hospitalization, it was offered at 32.5% of departments, rising to 60.7% in centers with over 1000 beds.
Sterile formulations were prepared in 82.3% of departments; 15.7% managed advanced therapies. Drug level monitoring was measured in 16.1%, and 43.1% issued pharmacokinetics reports. Pharmacogenetic reports were produced in 8.7%.
On average pharmacy departments attended 3.635 outpatients, totaling 1,28 million nationwide. Cytostatic preparations averaged 31,199 and 46,263 in hospitals with over 500 and 1000 beds, respectively. Clinical trials per department averaged 424.
A total of 321 pharmacists were associate university professors, 401 held board certifications, and there were 2.3 PhD holders per department.
Conclusions
Hospital Pharmacy Departments are advancing in clinical integration, pharmacokinetics, automation, traceability, and outpatient care, though staffing remains limited and disparities persist. Teaching is strong, yet research remains modest.
{"title":"[Artículo traducido] Encuesta Nacional de la SEFH 2022 sobre los servicios de farmacia hospitalaria en España: recursos humanos, infraestructura, tecnología, sistemas de información, docencia e investigación","authors":"Montserrat Pérez-Encinas , Eva Negro-Vega , Cecilia M. Fernández-Llamazares","doi":"10.1016/j.farma.2025.08.002","DOIUrl":"10.1016/j.farma.2025.08.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To present results of the 2022 SEFH-Survey on Spanish Hospital Pharmacy Departments covering care, staffing, resources, technology, education, and research.</div></div><div><h3>Method</h3><div>A cross-sectional descriptive study via a voluntary online survey sent to 353 hospitals in Spain. Data were collected from July–December 2022. Long-stay hospitals and correctional facilities were excluded.</div></div><div><h3>Results</h3><div>Response rate was 54.1%. Public hospitals represented 62.6%. Only 10.1% of departments operated 24/7, rising to 39.3% in larger hospitals. Half lacked continuous care service. Outpatients' services operated in mornings and afternoons in 54.8% of them (78.6% in larger centers). Telepharmacy for outpatients reached 57.7% of hospitals. ISO 9000 standards were followed by 70.7% and 14.4% adopted the Joint Commission model.</div><div>Each department had on average 7.0 specialist pharmacists (8.8 in public hospitals; 3.9 in private), increasing to 13.4 in larger hospitals. Of these, 3.8 pharmacists worked at least half-time in clinical units. Pharmacy technicians were the most common non-pharmacist professionals (mean: 6.9). Including residents, 9.936 professionals worked in Hospital Pharmacy Departments nationwide.</div><div>Automated dispensing carousels averaged 0.4 (horizontal) and 1.1 (vertical) per department. Automated dispensing systems covered 19.8% of beds. Robotic outpatient dispensing existed in 20.0% of hospitals. Technology for sterile workflow was used in 45.3%, 10.0% had robotics for cytostatic compounding and 61.7% smart infusion pumps.</div><div>Pharmaceutical care was provided in emergency services in 39.8% of hospitals, rising to 67.4 in larger ones. In home hospitalization, it was offered at 32.5% of departments, rising to 60.7% in centers with over 1000 beds.</div><div>Sterile formulations were prepared in 82.3% of departments; 15.7% managed advanced therapies. Drug level monitoring was measured in 16.1%, and 43.1% issued pharmacokinetics reports. Pharmacogenetic reports were produced in 8.7%.</div><div>On average pharmacy departments attended 3.635 outpatients, totaling 1,28 million nationwide. Cytostatic preparations averaged 31,199 and 46,263 in hospitals with over 500 and 1000 beds, respectively. Clinical trials per department averaged 424.</div><div>A total of 321 pharmacists were associate university professors, 401 held board certifications, and there were 2.3 PhD holders per department.</div></div><div><h3>Conclusions</h3><div>Hospital Pharmacy Departments are advancing in clinical integration, pharmacokinetics, automation, traceability, and outpatient care, though staffing remains limited and disparities persist. Teaching is strong, yet research remains modest.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T312-T320"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.06.010
Claudia Colomer Aguilar , Eva Negro-Vega , Edurne Fernández de Gamarra-Martínez , Beatriz Martínez Castro , María Pérez Abánades , Susana Redondo Capafons , Covadonga Pérez Menéndez Conde
Objective
Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy residents, serving as a guideline and reference for hospital pharmacy tutors.
Method
A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.
Results
The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/administration, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Rotations not included in the official programme are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.
Conclusions
This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.
{"title":"[Translated article] Map of the residency rotations for hospital pharmacy residents in Spain","authors":"Claudia Colomer Aguilar , Eva Negro-Vega , Edurne Fernández de Gamarra-Martínez , Beatriz Martínez Castro , María Pérez Abánades , Susana Redondo Capafons , Covadonga Pérez Menéndez Conde","doi":"10.1016/j.farma.2025.06.010","DOIUrl":"10.1016/j.farma.2025.06.010","url":null,"abstract":"<div><h3>Objective</h3><div>Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy residents, serving as a guideline and reference for hospital pharmacy tutors.</div></div><div><h3>Method</h3><div>A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.</div></div><div><h3>Results</h3><div>The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/administration, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Rotations not included in the official programme are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.</div></div><div><h3>Conclusions</h3><div>This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T291-T298"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.05.010
Irene de la Fuente Villaverde , Alicia Caso González , Mónica Carbajales Álvarez , Alba Martínez Torrón , Sergio Fernández Lastras , Juan Luis García Llano , Ana Lozano Blázquez
Introduction
Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with BRAF V600 mutation. Its experience of use in glioblastomas is very limited.
We present the case of a patient diagnosed with BRAF V600 mutated glioblastoma who progressed to standard therapy. After starting treatment with vemurafenib in June 2022, the patient currently maintains a good clinical situation and the disease remains stable, with no progression observed.
Discussion
There is little literature supporting the efficacy of vemurafenib in BRAF 600 mutated glioblastomas. Published data suggest promising results, although survival in these patients remains low. This patient's progression-free survival is one of the longest documented to date.
{"title":"[Translated article] Vemurafenib for the treatment of BRAF V600 mutated glioblastoma: A case report","authors":"Irene de la Fuente Villaverde , Alicia Caso González , Mónica Carbajales Álvarez , Alba Martínez Torrón , Sergio Fernández Lastras , Juan Luis García Llano , Ana Lozano Blázquez","doi":"10.1016/j.farma.2025.05.010","DOIUrl":"10.1016/j.farma.2025.05.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with <em>BRAF</em> V600 mutation. Its experience of use in glioblastomas is very limited.</div><div>We present the case of a patient diagnosed with BRAF V600 mutated glioblastoma who progressed to standard therapy. After starting treatment with vemurafenib in June 2022, the patient currently maintains a good clinical situation and the disease remains stable, with no progression observed.</div></div><div><h3>Discussion</h3><div>There is little literature supporting the efficacy of vemurafenib in BRAF 600 mutated glioblastomas. Published data suggest promising results, although survival in these patients remains low. This patient's progression-free survival is one of the longest documented to date.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T346-T348"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.02.010
Héctor Carlos García-Díaz , María Larrosa-Garcia , Javier Gómez-Alonso , Mara Cruellas , Enriqueta Felip , Teresa Macarulla , Anna Farriols , Maria J. Carreras
Objective
To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.
Methods
A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.
Results
A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of BRCA2 (PALB2) intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (ATM) non-small cell lung adenocarcinoma, somatic breast cancer gene (sBRCA2) colorectal cancer, germinal breast cancer gene 2 (gBRCA2) breast neuroendocrine tumor, gBRCA2 ampullary cancer and gBRCA2 pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.
Conclusions
There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes, like PALB2 and ATM and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.
{"title":"Off-label use of olaparib in uncommon tumor locations in patients with impaired homologous recombination genes","authors":"Héctor Carlos García-Díaz , María Larrosa-Garcia , Javier Gómez-Alonso , Mara Cruellas , Enriqueta Felip , Teresa Macarulla , Anna Farriols , Maria J. Carreras","doi":"10.1016/j.farma.2025.02.010","DOIUrl":"10.1016/j.farma.2025.02.010","url":null,"abstract":"<div><h3>Objective</h3><div>To describe the effectiveness and safety of olaparib off-label indications in patients with impaired homologous recombination genes and solid tumors different than those authorized.</div></div><div><h3>Methods</h3><div>A single-center, observational and retrospective study including patients treated with olaparib for off-label use. The main variables were patient characteristics, prior therapies, response to therapy, progression-free survival, overall survival and adverse events.</div></div><div><h3>Results</h3><div>A total of 6 patients were included. All patients had metastases and received 3 or more lines of prior treatment. The primary tumor locations and mutations were partner and localizer of <em>BRCA2</em> (<em>PALB2)</em> intrahepatic cholangiocarcinoma, ataxia telangiectasia mutated (<em>ATM)</em> non-small cell lung adenocarcinoma, somatic breast cancer gene (<em>sBRCA2)</em> colorectal cancer, germinal breast cancer gene 2 (<em>gBRCA2)</em> breast neuroendocrine tumor, <em>gBRCA2</em> ampullary cancer and <em>gBRCA2</em> pancreatic neuroendocrine tumor. At the end of the study, one patient was still receiving olaparib showing more than 25 months of sustained stable disease response. No novel toxicities were observed besides those included in the product information.</div></div><div><h3>Conclusions</h3><div>There is limited published evidence on the use of olaparib in patients harboring pathogenic variants other than breast cancer genes<em>,</em> like <em>PALB2</em> and <em>ATM</em> and conditions different than those authorized such as digestive tract, neuroendocrine and lung tumors. Further research is to assess the efficacy of olaparib in these patients.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 286-290"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"ARN mensajero como nueva estrategia contra el cáncer","authors":"Eduardo Tejedor Tejada , Begoña Gómez Pérez , Garbiñe Lizeaga Cundin","doi":"10.1016/j.farma.2024.10.007","DOIUrl":"10.1016/j.farma.2024.10.007","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Page 350"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.03.014
Claudia Colomer Aguilar , Eva Negro-Vega , Edurne Fernández de Gamarra-Martínez , Beatriz Martínez Castro , María Pérez Abánades , Susana Redondo Capafons , Covadonga Pérez Menéndez Conde
Objective
Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy interns, serving as a guideline and reference for hospital pharmacy tutors.
Method
A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.
Results
The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/leadership, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Non-programmed rotations are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.
Conclusions
This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.
{"title":"Mapa de las rotaciones de los farmacéuticos internos residentes de farmacia hospitalaria en España","authors":"Claudia Colomer Aguilar , Eva Negro-Vega , Edurne Fernández de Gamarra-Martínez , Beatriz Martínez Castro , María Pérez Abánades , Susana Redondo Capafons , Covadonga Pérez Menéndez Conde","doi":"10.1016/j.farma.2025.03.014","DOIUrl":"10.1016/j.farma.2025.03.014","url":null,"abstract":"<div><h3>Objective</h3><div>Collecting updated information on the organization of Hospital Pharmacy specialty rotations in different areas across Spanish hospitals, in order to create a map of residency rotations for hospital pharmacy interns, serving as a guideline and reference for hospital pharmacy tutors.</div></div><div><h3>Method</h3><div>A cross-sectional, multicenter descriptive study on the planning of residency rotations for hospital pharmacy interns in hospitals accredited for specialized healthcare training in Spain. An online survey was designed and distributed via mailing list by the Spanish Society of Hospital Pharmacy between May and June 2024. The survey, validated and tested in a pilot sample, gathered general information about the hospital, rotations by areas of activity (year of residency, duration, complete/partial modality, shared rotations), external and elective rotations, additional training, supervision and assessment of the residents. Data were analyzed descriptively, including measures of central tendency and dispersion for quantitative variables and frequencies for categorical variables.</div></div><div><h3>Results</h3><div>The response rate was 86.8%. A basic initial rotation is present in 88.9% of hospitals, with a median duration of 6.5 weeks. Stock management, compounding, and validation and dispensing to inpatients are primarily carried out during the first year, while nutrition and oncology are concentrated in the 2nd year. Outpatient pharmaceutical care, clinical trials, medication evaluation and selection, drug information, and pharmacokinetics are conducted in the third year, whereas management/leadership, primary care, and pharmaceutical care in clinical units are undertaken in the 4th year. The most common clinical rotations include Infectious Diseases (70.7%) and Hematology (67.7%). The duration of rotations varies between 1 and 9 months, with many organized as shared rotations, particularly in drug information and medication evaluation. Non-programmed rotations are included in 93.3% of hospitals, 91.9% of residents participate in clinical committees, and 22.2% have the opportunity to pursue a PhD.</div></div><div><h3>Conclusions</h3><div>This study shows considerable variability in the organization of training programs across hospital pharmacy teaching units in Spain.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 291-298"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.04.001
Paloma Suárez-Casillas , Santiago José Lora-Escobar , Elena Montecatine-Alonso , Tao Li , Hector Acosta-García
Purpose
The aim of this study was to review and compile the available information, in an easily accessible format, regarding the stability of thermolabile drugs at room temperature (22–25 °C), according to information contained in summary of product characteristics (SmPC), published literature, and information provided by the manufacturing pharmaceutical companies.
Methods
Drugs included in our hospital that required storage at a temperature between 2 and 8 °C were selected. Medications used in clinical trials, frozen drugs, and compounded formulations were excluded. The first source of information consulted for stability data was the SmPC. In case of no information available, published literature and gray literature were reviewed. If information was not found through these sources, the manufacturing laboratory was contacted.
The results are shown in table format to make the information more manageable. The table contains the following information: Drug product, trade name, brand name (manufacturer), maximum stability at room temperature, and information source. Stability data from SmPC were included for all medications, and for those with additional information obtained through the sources used in the study, this was included in a separate column.
Results
A total of 203 thermolabile drugs were selected. Thirty seven (18.2%) had a stability of 24 h at room temperature, 36 (17.7%) had a stability of 48 h–1 week, 63 (31%) had a stability of 1 week–1 month, and 52 (25.6%) had a stability of more than 1 month. However, 12 drugs (6.3%) had a stability of less than 24 h, and 3 drugs (1.4%) had other stability data at room temperature.
Stability information for 95 (46.7%) drugs was obtained from the SmPC, 56 (27.5%) from published literature, and 36 (26.2%) from manufacturers. In 21 of these cases, the stability information was valid exclusively for a specific case, with particular storage conditions and for a specific batch of the product.
Conclusion
The number and impact of thermolabile drugs have increased exponentially in recent years. The vast majority of these drugs maintain adequate stability at room temperature for an acceptable period of time, with some remaining stable for relatively long periods. To date, our study presents the largest dataset on the stability of these drugs. Therefore, the results of our study constitute a highly useful and up-to-date tool for saving time and money in hospital pharmacy units. Pharmaceutical manufacturers should consider publishing stability study results under non-recommended storage conditions in the SmPC.
{"title":"[Artículo traducido] Estabilidad de los medicamentos termolábiles a temperatura ambiente. Revisión","authors":"Paloma Suárez-Casillas , Santiago José Lora-Escobar , Elena Montecatine-Alonso , Tao Li , Hector Acosta-García","doi":"10.1016/j.farma.2025.04.001","DOIUrl":"10.1016/j.farma.2025.04.001","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim of this study was to review and compile the available information, in an easily accessible format, regarding the stability of thermolabile drugs at room temperature (22–25 °C), according to information contained in summary of product characteristics (SmPC), published literature, and information provided by the manufacturing pharmaceutical companies.</div></div><div><h3>Methods</h3><div>Drugs included in our hospital that required storage at a temperature between 2 and 8 °C were selected. Medications used in clinical trials, frozen drugs, and compounded formulations were excluded. The first source of information consulted for stability data was the SmPC. In case of no information available, published literature and gray literature were reviewed. If information was not found through these sources, the manufacturing laboratory was contacted.</div><div>The results are shown in table format to make the information more manageable. The table contains the following information: Drug product, trade name, brand name (manufacturer), maximum stability at room temperature, and information source. Stability data from SmPC were included for all medications, and for those with additional information obtained through the sources used in the study, this was included in a separate column.</div></div><div><h3>Results</h3><div>A total of 203 thermolabile drugs were selected. Thirty seven (18.2%) had a stability of 24 h at room temperature, 36 (17.7%) had a stability of 48 h–1 week, 63 (31%) had a stability of 1 week–1 month, and 52 (25.6%) had a stability of more than 1 month. However, 12 drugs (6.3%) had a stability of less than 24 h, and 3 drugs (1.4%) had other stability data at room temperature.</div><div>Stability information for 95 (46.7%) drugs was obtained from the SmPC, 56 (27.5%) from published literature, and 36 (26.2%) from manufacturers. In 21 of these cases, the stability information was valid exclusively for a specific case, with particular storage conditions and for a specific batch of the product.</div></div><div><h3>Conclusion</h3><div>The number and impact of thermolabile drugs have increased exponentially in recent years. The vast majority of these drugs maintain adequate stability at room temperature for an acceptable period of time, with some remaining stable for relatively long periods. To date, our study presents the largest dataset on the stability of these drugs. Therefore, the results of our study constitute a highly useful and up-to-date tool for saving time and money in hospital pharmacy units. Pharmaceutical manufacturers should consider publishing stability study results under non-recommended storage conditions in the SmPC.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T328-T338"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144162745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.farma.2025.06.008
Núria Farré Cabrerizo, Olalla Montero Pérez, Maria Emilia Miquel Zurita, Marina Badàs Moreno, Marta Company Martos, Gemma Garcia Deu, Jennifer Rodríguez Rojas, Mònica González Laguna, Sonia Narváez Seixa, Sandra Fontanals Martínez, Maria Perayre Badia
In recent years, there has been a considerable increase in clinical trials in the field of oncohematology, an area in which new drugs are constantly emerging. In addition to the large number of available clinical trials, the growing complexity of the treatments for cancer is also a relevant factor. This situation has required a notable evolution and specialization of the functions and responsibilities of pharmacy technicians within the Clinical Trials Unit of the Pharmacy Service.
This article describes the role of the pharmacy technician in a Clinical Trials Unit of tan oncohematological hospital pharmacy service, with over 20 years of experience in clinical trials.
{"title":"[Translated article] Role of the pharmacy technician in the clinical trials unit of the pharmacy service of an oncohaematological hospital","authors":"Núria Farré Cabrerizo, Olalla Montero Pérez, Maria Emilia Miquel Zurita, Marina Badàs Moreno, Marta Company Martos, Gemma Garcia Deu, Jennifer Rodríguez Rojas, Mònica González Laguna, Sonia Narváez Seixa, Sandra Fontanals Martínez, Maria Perayre Badia","doi":"10.1016/j.farma.2025.06.008","DOIUrl":"10.1016/j.farma.2025.06.008","url":null,"abstract":"<div><div>In recent years, there has been a considerable increase in clinical trials in the field of oncohematology, an area in which new drugs are constantly emerging. In addition to the large number of available clinical trials, the growing complexity of the treatments for cancer is also a relevant factor. This situation has required a notable evolution and specialization of the functions and responsibilities of pharmacy technicians within the Clinical Trials Unit of the Pharmacy Service.</div><div>This article describes the role of the pharmacy technician in a Clinical Trials Unit of tan oncohematological hospital pharmacy service, with over 20 years of experience in clinical trials.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages T321-T327"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medication reconciliation is relevant in transitional care, however, given limited resources, it is necessary to identify the patients who benefit most from this activity.
Aim
To validate criteria to identify patients at high risk of medication errors undergoing major orthopedic surgery.
Method
Delphi Method in 3 phases, April–June 2023, to obtain consensus on the inclusion criteria, previously defined. Each expert rated criteria according to a 5-point Likert scale. Consensus was assumed in round 1 if the rate average was ≥ 4 (inclusion) or < 2 (exclusion) and in rounds 2 and 3 if 50% of the responses were ≥ 4 (inclusion) or < 2 (exclusion). It was possible to suggest the inclusion of new criteria.
Results
10 experts from Faculties of Pharmacy and Medicine participated. In the first phase, consensus was reached on 18 criteria: polypharmacy, anticoagulants, oral chemotherapy (not hormone), immunosuppressants, antiretrovirals, antimyasthenics, insulin, corticoids, neuroleptics, antiarrhythmics, digoxin, carbamazepine, phenytoin, valproate, thyroid drugs, antiglaucoma, antiaggregants, and urgent surgery. Systemic antifungals and opioids were suggested. In the second phase, consensus was reached on 11 criteria: antiparkinsonics, beta-blockers, age ≥ 65 years, length of stay ≥ 5 days, lamotrigine, diuretics, antidepressants, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, anxiolytics, opioids, and systemic antifungals. In the last phase, 1 criterion reached consensus (sulfonylureas) and 1 criterion did not reach consensus (calcium channel blockers).
Conclusions
We develop and validate a list of 30 criteria to identify patients at high risk of experiencing medication errors undergoing major orthopedic surgery. These may help improve human resource management for clinical pharmacy activities by prioritizing patients who would benefit most.
{"title":"Criteria for medication reconciliation in major orthopedic surgery in high-risk patients: A consensus based on the Delphi method","authors":"Mafalda Cavalheiro , Jesús Cotrina Luque , Gonçalo Duarte , Patricia BSilva , Cátia Pereira , Miriam Capoulas , Cláudia Santos","doi":"10.1016/j.farma.2024.10.016","DOIUrl":"10.1016/j.farma.2024.10.016","url":null,"abstract":"<div><h3>Background</h3><div>Medication reconciliation is relevant in transitional care, however, given limited resources, it is necessary to identify the patients who benefit most from this activity.</div></div><div><h3>Aim</h3><div>To validate criteria to identify patients at high risk of medication errors undergoing major orthopedic surgery.</div></div><div><h3>Method</h3><div>Delphi Method in 3 phases, April–June 2023, to obtain consensus on the inclusion criteria, previously defined. Each expert rated criteria according to a 5-point Likert scale. Consensus was assumed in round 1 if the rate average was ≥<!--> <!-->4 (inclusion) or <<!--> <!-->2 (exclusion) and in rounds 2 and 3 if 50% of the responses were ≥<!--> <!-->4 (inclusion) or <<!--> <!-->2 (exclusion). It was possible to suggest the inclusion of new criteria.</div></div><div><h3>Results</h3><div>10 experts from Faculties of Pharmacy and Medicine participated. In the first phase, consensus was reached on 18 criteria: polypharmacy, anticoagulants, oral chemotherapy (not hormone), immunosuppressants, antiretrovirals, antimyasthenics, insulin, corticoids, neuroleptics, antiarrhythmics, digoxin, carbamazepine, phenytoin, valproate, thyroid drugs, antiglaucoma, antiaggregants, and urgent surgery. Systemic antifungals and opioids were suggested. In the second phase, consensus was reached on 11 criteria: antiparkinsonics, beta-blockers, age ≥ 65 years, length of stay ≥<!--> <!-->5 days, lamotrigine, diuretics, antidepressants, angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, anxiolytics, opioids, and systemic antifungals. In the last phase, 1 criterion reached consensus (sulfonylureas) and 1 criterion did not reach consensus (calcium channel blockers).</div></div><div><h3>Conclusions</h3><div>We develop and validate a list of 30 criteria to identify patients at high risk of experiencing medication errors undergoing major orthopedic surgery. These may help improve human resource management for clinical pharmacy activities by prioritizing patients who would benefit most.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 272-277"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142755518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号